RESUMO
AIM: To evaluate the impact of using the innovative antiviral drugs in patients with chronic hepatitis C (CHC) on the disease burden in the long term. MATERIALS AND METHODS: A program was developed to increase the availability of innovative antiviral therapy (AVT) in patients with CHC covering the period from 2013 to 2020. To evaluate the impact of the program on the burden of hepatitis C (HC) in the Russian Federation, a Markov model of the disease progression was developed till 2030. Calculations were made in medical and social perspectives. RESULTS: The implementation of the program will allow to decrease the medical costs by RBL 2 billion and budget costs, including disability payments, by RBL 3.8 billion by 2030. During this period, in GDP losses will decrease by RBL 1.1 trillion and the total burden of HC taking into account the cost of the program by RBL 1 trillion. CONCLUSION: For the first time it was shown that the expanding coverage of CHC patients with innovative AVT will allow to reduce the costs of health and social services.
Assuntos
Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Hepatite C Crônica/economia , Efeitos Psicossociais da Doença , Progressão da Doença , Custos de Cuidados de Saúde/tendências , Hepatite C Crônica/epidemiologia , Humanos , Desenvolvimento de Programas , Avaliação de Programas e Projetos de Saúde , Federação Russa/epidemiologiaRESUMO
The results of the comparative study of the prevalence and risk factors of epilepsy in adults in the Republic of Kazakhstan and the Russian Federation revealed that the consequences of perinatal pathology was the main risk factor in young patients while the consequences of brain injury or cerebrovascular disease predicted epilepsy in middle age and elderly people, respectively. These data may be used for prediction of course of epilepsy provided that long-term and careful studies on the dynamics of above-mentioned indicators will be carried out.